ImmunoQure AG announces publication in leading scientific journal of findings that demonstrate autoantibody responses against multiple proteins in APECED/APS-1 patients

Düsseldorf, Germany August 16, 2017.

ImmunoQure AG, a biotechnology company focused on the development of autoantibodies as therapeutics to treat human diseases today announced the publication of data in the leading scientific journal Frontiers in Immunology.

ImmunoQure’s focus is the identification and development of autoantibodies derived from an ultra rare patient population with an autoimmune disorder called autoimmune polyendocrine syndrome type 1 (APS1 or APECED). APS-1 patients have a mutation in the AIRE gene which is involved in controlling central tolerance – a key mechanism used by the human immune system to filter out immune cells that have the potential to target the body’s own proteins (“self proteins”) rather than those which are not (“non-self proteins”) e.g., from infectious agents such as bacteria or viruses.